The Oncomine Focus Assay is a targeted, multi-biomarker assay that enables detection of hotspots, SNVs, indels, CNVs, and gene fusions from DNA and RNA in a single workflow. This comprehensive assay design is further enhanced with workflow automation, delivering insights quickly and helping accelerate your research towards that next companion diagnostic or therapy in the future.

4-5 weeks

NGS

FFPE fine needle aspirates and core needle biopsies

No. of genes:52 AKT1, ALK, AR, AX, BRAF, CCND1, CDK4, CDK6, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGFR4, GNA11, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, MYC, MYCN, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PIK3CA, PPARG, RAF1, RET, ROS1, SMO

The JAK2 mutation test is a diagnostic test used to detect mutations in the Janus kinase 2 (JAK2) gene. This gene encodes a protein involved in signaling pathways that regulate blood cell production. Mutations in the JAK2 gene are commonly associated with myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The primary genetic test for JAK2 mutations that lead to MPNs is JAK2 V617F, named for a mutation at a specific location in the JAK2 gene. It is typically ordered first. If it is negative, then tests for other mutations in the JAK2 gene that are also associated with MPNs, such as JAK2 exon 12, may be used to help make a diagnosis.

5 business days

Polymerase chain reaction (PCR)

EDTA Blood, DNA